The virus that causes COVID-19 can develop partial resistance to the antiviral drug remdesivir during infection of cultured cells in the laboratory by more than one mechanism.
The results of the laboratory study led by researchers at Vanderbilt University Medical Center and published April 28 in the journal Science Translational Medicine support the importance of monitoring for resistance and its mechanisms, tracking specific mutations and developing combination therapies.